Mohammed Hamsho

Dr. Mohammed Hamsho


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2025 in Food Science & Nutrition
Verified
Journal Article
Open access
WSWijdan Shkorfu
Wijdan Shkorfu
AFAbdulmannan Fadel
Abdulmannan Fadel
MHMohammed Hamsho
Mohammed Hamsho
YRYazan Ranneh
Yazan Ranneh
HSHafiz Muhammad Shahbaz
Hafiz Muhammad Shahbaz
Intermittent fasting (IF), a temporal dietary pattern, has garnered interest in improving anthropometric and metabolic markers. Beyond this, IF appears to recalibrate hormonal circadian rhythms and reshape gut microbiota—two key intermediaries through which IF exerts effects on endocrine, inflammatory, and oncogenic pathways. This review synthesizes research findings of IF on key endocrine systems and outlines its potential implications for oncogenic risk. We primarily examine the effects of IF on hormonal regulation with a particular focus on its relevance to metabolic and oncogenic health outcomes. We explored hormonal alterations induced by various IF protocols and discussed their physiological implications. Controlled observations or interventional studies in both human and animal models were included. Evidence indicates that IF exerts systemic effects on hormonal rhythmicity, including insulin, thyroid hormones, glucocorticoids, and sex hormones, potentially re‐establishing homeostatic endocrine function. Moreover, IF influences cancer‐related pathways via modulation of endocrine axes and attenuation of inflammatory markers. These mechanisms offer a theoretical basis for IF's potential in attenuating metabolic dysfunction and cancer risk. However, the current research is limited by variations in study designs, short durations, limited cohorts, and population‐specific findings, restricting generalizability and applicability. Ultimately, IF represents a multifaceted dietary strategy with the potential to synchronize circadian and hormonal systems, positioning it as a promising intervention in metabolic and endocrine‐related conditions. However, whether long‐term IF can modulate specific hormonal axes without overt physiological side effects, including sex‐specific effects, remains unclear. To establish its clinical relevance and therapeutic safety, validation through well‐designed and large‐scale human trials is imperative.

23 November 2024 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Open access
MHMohammed Hamsho
Mohammed Hamsho
WSWijdan Shkorfu
Wijdan Shkorfu
YRYazan Ranneh
Yazan Ranneh
AFAbdulmannan Fadel
Abdulmannan Fadel
Intermittent fasting (IF) has been demonstrated to enhance human health through several mechanisms. However, it is still unclear whether those health benefits are independent of caloric restriction (CR)-induced weight loss. This systematic review and meta-analysis aimed to compare isocaloric IF and CR regarding anthropometric measurements, adherence, metabolic profile, inflammatory biomarkers, and adipokines in adults and elderlies. Comprehensive research was conducted usin four major databases including Embase, PubMed, Scopus, and Google Scholar without date restriction. Mean differences of the change from baseline ± change SD were calculated as the differences between IF and CR groups. Subgroup analysis was performed according to intervention duration (short-, medium-, and long-term). To determine the reliability of our findings, GRADE assessment was performed. As a result, 20 RCTs were included in this systematic review and meta-analysis. IF groups had significant reductions in fat mass (kg) (P = 0.006) and Interleukin-6 (P < 0.00001) in the short term and fat mass (%) (P = 0.0002), waist circumference (P = 0.005), fasting blood insulin (P < 0.00001) and HOMA-IR (P = 0.04) in the long term. CR groups had significantly lower hunger (P = 0.003), fatigue (P = 0.04), and TG (P = 0.03). IF may be an effective alternative to CR but is not superior to CR in enhancing human health. Due to the low number of long-term studies, future studies should focus on conducting longitudinal randomized trials comparing IF and CR in different populations, age groups, and IF patterns.

25 July 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
YRYazan Ranneh
Yazan Ranneh
MHMohammed Hamsho
Mohammed Hamsho
WSWijdan Shkorfu
Wijdan Shkorfu
MTMerve Terzi
Merve Terzi
AFAbdulmannan Fadel
Abdulmannan Fadel
Background: Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder characterized by excess body weight, hyperandrogenism, hyperglycemia, and insulin resistance often resulting in hirsutism and infertility. Dietary strategies have been shown to ameliorate metabolic disturbances, hormonal imbalances, and inflammation associated with PCOS. Recent evidence indicates that intermittent fasting (IF) could effectively enhance health outcomes and regulate circadian rhythm; however, its impact on PCOS remain unclear. Objective: Therefore, this systematic review and meta-analysis aims to examine the effect of IF on women diagnosed with PCOS. Methods: Comprehensive research was conducted across three major databases including PubMed, Scopus, and Web of Science without date restrictions. Meta-analysis was performed using Cochrane Review Manager Version 5.4 software. Results: Five studies fulfilled the inclusion criteria. IF significantly reduced body weight (MD = −4.25 kg, 95% CI: −7.71, −0.79; p = 0.02), BMI (MD = −2.05 kg/m2, 95% CI: −3.26, −0.85; p = 0.0008), fasting blood glucose (FBG; MD = −2.86 mg/dL, 95% CI: −4.83, −0.89; p = 0.004), fasting blood insulin (FBI; MD = −3.17 μU/mL, 95% CI: −5.18, −1.16; p = 0.002), insulin resistance (HOMA-IR; MD = −0.94, 95% CI: −1.39, −0.50; p < 0.0001), triglycerides (TG; MD = −40.71 mg/dL, 95% CI: −61.53, −19.90; p = 0.0001), dehydroepiandrosterone sulfate (DHEA-S; MD = −33.21 μg/dL, 95% CI: −57.29, −9.13; p = 0.007), free androgen index (FAI; MD = −1.61%, 95% CI: −2.76, −0.45; p = 0.006), and C-reactive protein (CRP; MD = −2.00 mg/L, 95% CI: −3.15, −0.85; p = 0.006), while increasing sex hormone-binding globulin (SHBG; SMD = 0.50, 95% CI: 0.22, 0.77; p = 0.004). No significant changes were observed in waist-to-hip ratio (WHR), total cholesterol (TC), LDL, HDL, total testosterone (TT), or anti-Mullerian hormone (AMH). Conclusions: IF represents a promising strategy for improving weight and metabolic, hormonal, and inflammatory profiles in women with PCOS. However, the existing evidence remains preliminary, necessitating further robust studies to substantiate these findings.

7 October 2025 in Endocrinología, Diabetes y Nutrición (English Ed.)
Verified
Journal Article
Closed access
MHMohammed Hamsho
Mohammed Hamsho
YRYazan Ranneh
Yazan Ranneh
AFAbdulmannan Fadel
Abdulmannan Fadel

26 June 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
MHMohammed Hamsho
Mohammed Hamsho
MBMeriem Bensaoua
Meriem Bensaoua
WSWijdan Shkorfu
Wijdan Shkorfu
YRYazan Ranneh
Yazan Ranneh
Faiza KalamFaiza Kalam
Faiza Kalam
Background: Polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), is a complex endocrine–metabolic disorder strongly associated with insulin resistance, hyperandrogenism, and obesity. Time-restricted eating (TRE) has emerged as a promising dietary strategy for improving metabolic health; however, evidence regarding its efficacy in women with PMOS remains limited. Objective: To systematically evaluate the effects of TRE on metabolic, hormonal, anthropometric, and adherence-related outcomes in women with PMOS. Methods: PubMed, Embase, Scopus, and Web of Science were systematically searched through 25 April 2026, for randomized controlled trials evaluating TRE interventions in women with PMOS. Random-effects meta-analyses were performed to pool mean differences (MD) with 95% confidence intervals for specific metabolic, hormonal, and anthropometric outcomes. Results: Four randomized controlled trials comprising 216 women with PMOS were included; three trials compared TRE with calorie restriction and one with ad libitum intake. Compared with control interventions, TRE significantly improved HOMA-IR (MD = −0.58, 95% CI: −0.87 to −0.30), QUICKI (MD = 0.08, 95% CI: 0.04 to 0.13), and HDL (MD = 1.97 mg/dL, 95% CI: 0.96 to 2.99). TRE was generally associated with high adherence across the included studies, with some trials reporting higher compliance than calorie restriction. Conclusions: Current evidence from four RCTs suggests that TRE may serve as a promising alternative dietary strategy for women with PMOS, particularly for improving insulin sensitivity. However, the evidence remains limited by the small number of available studies, modest sample sizes, and heterogeneity across interventions. Therefore, these findings should be considered preliminary and require confirmation in a larger, longer-term randomized controlled trial.

1 March 2024 in American Journal of Men's Health
Verified
Journal Article
Open access
MHMohammed Hamsho
Mohammed Hamsho
YRYazan Ranneh
Yazan Ranneh
AFAbdulmannan Fadel
Abdulmannan Fadel